Skip to content

Life Style Modification Medical and Surgical Management in Patients With Obesity

Evaluation of Life Style Modification Medical and Surgical Treatment Modalities in Patients With Obesity: An Observational Study

Status
UNKNOWN
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT04417582
Enrollment
1000
Registered
2020-06-04
Start date
2020-01-01
Completion date
2025-12-01
Last updated
2020-06-04

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Obesity, Obesity; Endocrine, Obesity, Metabolically Benign, Weight Change, Body

Keywords

obesity, weight loss

Brief summary

In this is an observational study, obese patients that administed and followed in endocrinology clinic of Marmara University Medical school hospital will follow for clinical and laboratory parameters prospectively for 5 years

Detailed description

Following available clinical and laboratory parameters will be collected for 5 years Treatment modalities ( life stye modification, medication, bariatric surgery) eating habits quality of life body mass index , blood pressure body fat distribution (impedance measurement) laboratory parameters (serum glucose, OGTT, insülin, lipids,creatinin ,ALT AST,CBC, ferritin calcium, phosphate, Parathormone,25 OH vitamin D, vitamin B12 ,uric acid, albumin, FSH LH testosteron, estrogen ) muscle strength (dynomometer measurement) skin glikolization autoflouresent measurement Bone mineral density mesurements (femur, spine ,forarm)

Interventions

PROCEDUREbariatric surgey

patients undergone bariatric surgery or prescribed antiobesity drugs

Sponsors

Marmara University
Lead SponsorOTHER

Study design

Observational model
COHORT
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
18 Years to 65 Years
Healthy volunteers
No

Inclusion criteria

Body mass index over 30 kg/m2 age between 18-65 years

Exclusion criteria

active malignancy pregnancy during involvement period chronic inflamatuar diseases

Design outcomes

Primary

MeasureTime frameDescription
weight loss6 months interval%5-10 weight loss
metabolic improvement6 months intervalblood glucose

Countries

Turkey (Türkiye)

Contacts

Primary ContactDilek Gogas Yavuz, MD
dilekgogas@marmara.edu.tr+902166254685

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026